BDBM802065 (2S,4R)-1-((S)-5-benzyl-3- cyclopropyl-7,7-dimethyl- 5,6,7,8-tetrahydro-4H-[1,2,3] triazolo[1,5-a][1,4]diazepine- 8-carbonyl)-4-hydroxy-N- ((S)-1-(4-(4-methylthiazol-5- yl)phenyl)ethyl)pyrrolidine-2- carboxamide::US20260108613, Compound A9

SMILES Cc1ncsc1c7ccc([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@H]6n4nnc(C3CC3)c4CN(Cc5ccccc5)CC6(C)C)cc7

InChI Key InChIKey=IEVZBVHCLRTLBR-UHFFFAOYSA-N

Data  1 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 1 hit for monomerid = 802065   

Targetvon Hippel-Lindau disease tumor suppressor(Human)
University of Michigan

US Patent
LigandChemical structure of BindingDB Monomer ID 802065BDBM802065((2S,4R)-1-((S)-5-benzyl-3- cyclopropyl-7,7-dimethy...)
Affinity DataIC50: 18.6nMAssay Description:JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
9/2/2026
Entry Details
US Patent